Since FAP and PSMA are both expressed in prostate cancer and other cancers such as pancreatic cancer [25,35,36,37,38], the use of PSMA/FAP bispecific radioligands is expected to increase lesion detection sensitivity and treatment efficacy. The gene discussed is FOLH1; the disease is prostate carcinoma.